Literature DB >> 24999373

New MRI Biomarkers Advance the Characterization of Parkinson Disease.

David A Ziegler1, Suzanne Corkin2.   

Abstract

The pathophysiology of idiopathic Parkinson disease (PD) is traditionally characterized as substantia nigra degeneration, but careful examination of the widespread neuropathological changes suggests individual differences in neuronal vulnerability. A major limitation to studies of disease progression in PD has been that conventional MRI techniques provide relatively poor contrast for the structures that are affected by the disease, and thus are not typically used in experimental or clinical studies. Here, we review the current state of structural MRI as applied to the analysis of the PD brain. We also describe a new multispectral MRI method that provides improved contrast for the substantia nigra and basal forebrain, which we recently used to show that these structures display different trajectories of volume loss early in the disease.

Entities:  

Year:  2013        PMID: 24999373      PMCID: PMC4078999          DOI: 10.17925/enr.2013.08.02.85

Source DB:  PubMed          Journal:  Eur Neurol Rev        ISSN: 1758-3837


  98 in total

Review 1.  Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions.

Authors:  G E Alexander; M D Crutcher; M R DeLong
Journal:  Prog Brain Res       Date:  1990       Impact factor: 2.453

2.  Mild cognitive impairment in the elderly is associated with volume loss of the cholinergic basal forebrain region.

Authors:  Kathrin Muth; Ralf Schönmeyer; Silke Matura; Corinna Haenschel; Johannes Schröder; Johannes Pantel
Journal:  Biol Psychiatry       Date:  2009-04-17       Impact factor: 13.382

3.  Connectivity-based segmentation of the substantia nigra in human and its implications in Parkinson's disease.

Authors:  Ricarda A Menke; Saad Jbabdi; Karla L Miller; Paul M Matthews; Mojtaba Zarei
Journal:  Neuroimage       Date:  2010-10-01       Impact factor: 6.556

4.  Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items.

Authors:  Frederick A Schmitt; Dag Aarsland; Kolbjørn S Brønnick; Xiangyi Meng; Sibel Tekin; Jason T Olin
Journal:  Am J Alzheimers Dis Other Demen       Date:  2010-04-14       Impact factor: 2.035

5.  Cholinergic-dependent cognitive deficits in Parkinson's disease.

Authors:  B Dubois; F Danzé; B Pillon; G Cusimano; F Lhermitte; Y Agid
Journal:  Ann Neurol       Date:  1987-07       Impact factor: 10.422

6.  Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease.

Authors:  T Arendt; V Bigl; A Arendt; A Tennstedt
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

7.  Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease.

Authors:  M E Kalaitzakis; L M Christian; L B Moran; M B Graeber; R K B Pearce; S M Gentleman
Journal:  Parkinsonism Relat Disord       Date:  2008-07-07       Impact factor: 4.891

8.  Effects of cholinergic enhancement on visual stimulation, spatial attention, and spatial working memory.

Authors:  P Bentley; M Husain; R J Dolan
Journal:  Neuron       Date:  2004-03-25       Impact factor: 17.173

9.  Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease.

Authors:  David A Ziegler; Julien S Wonderlick; Paymon Ashourian; Leslie A Hansen; Jeremy C Young; Alex J Murphy; Cecily K Koppuzha; John H Growdon; Suzanne Corkin
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

10.  Clinical usefulness of magnetic resonance imaging in multiple system atrophy.

Authors:  A Schrag; D Kingsley; C Phatouros; C J Mathias; A J Lees; S E Daniel; N P Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.